PHS
ITOS

PFM Health Sciences’s iTeos Therapeutics ITOS Stock Holding History

PFM Health Sciences’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-70,922
Closed -$1.39M – 89
2022
Q4 		$1.39M Sell
70,922
-467,032
-87% -$9.13M 0.05% 80
2022
Q3 		$10.2M Hold
537,954
– – 0.37% 62
2022
Q2 		$11.1M Buy
+537,954
New +$12.8M 0.42% 58
2021
Q2 		– Sell
-232,216
Closed -$7.94M – 93
2021
Q1 		$7.94M Buy
+232,216
New +$8.39M 0.24% 73
2020
Q4 		– Sell
-406,467
Closed -$10M – 93
2020
Q3 		$10M Buy
+406,467
New +$10.9M 0.46% 60

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

PFM Health Sciences's ITOS Position: Q1 2023 in Review

PFM Health Sciences sold out of iTeos Therapeutics (ITOS) in Q1 2023, closing a stake of 70,922 shares — an estimated $1.39M sold.

PFM Health Sciences first reported a position in ITOS in Q3 2020 and held it in 5 quarters. The position peaked at $11.1M in Q2 2022. 153 funds tracked by Wall St. Rank hold ITOS as of Q1 2023.

  • PFM Health Sciences reported no remaining iTeos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • PFM Health Sciences sold 70,922 iTeos Therapeutics shares in Q1 2023, an estimated $1.39M.
  • PFM Health Sciences first reported a position in iTeos Therapeutics in Q3 2020 and held it in 5 quarters.
  • PFM Health Sciences's iTeos Therapeutics position peaked at $11.1M in Q2 2022.
  • 153 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2023.

Based on PFM Health Sciences's 13F filing for Q1 2023, filed 15 May 2023.